Investment in Anthos Therapeutics

RNS Number : 3619K

Schroder UK Public Private Tst plc

20 December 2022

 

20 December 2022

Schroder UK Public Private Trust plc

Investment in Anthos Therapeutics

Schroder UK Public Private Trust plc (the "Company") is pleased to announce it has made a commitment of $2.8 million (£2.3 million) to US-based, clinical-stage biopharmaceutical company, Anthos Therapeutics LLC ("Anthos"), in its Series B financing round.

Anthos' mission is to develop innovative therapies to advance care for people living with cardiovascular and metabolic diseases. Their most advanced program is focused on developing abelacimab, an investigational monoclonal antibody that inhibits coagulation Factor XI and its activated form, Factor XIa. Abelacimab is an experimental, next-generation anticoagulant with the potential to provide 'hemostasis-sparing anticoagulation': protection from arterial and venous thromboembolic events with a reduced risk of clinically-significant bleeding.

The Company is committed to reporting on its sustainability profile and discloses, where appropriate, the United Nations' Sustainable Development Goals ("SDGs") associated with all investments. The investment in Anthos is in line with SDG 3 "Good health and well-being", specifically Target 3.4 "Reduce mortality from non-communicable diseases and promote mental health" and Target 3.B "Support research, development and universal access to affordable vaccines and medicines".

The investment in Anthos is in line with the Company's private equity sub-strategy for backing innovative life sciences businesses, at the clinical or near-clinical stage, with high quality science and, a strong financing position.

Enquiries:

Schroder Investment Management Limited

Augustine Chipungu (Press)	0207 658 2106
John Spedding	0207 658 3206

 

END

 

 

ACQFLFEVFTLIFIF